Literature DB >> 24263169

Nebulized voriconazole in infections with Scedosporium apiospermum--case report and review of the literature.

J Holle1, M Leichsenring2, P E Meissner2.   

Abstract

Scedosporium infections are rare complications in immunocompromised patients or patients with chronic pulmonary disease. While Scedosporium prolificans is resistant to most antimycotics, Scedosporium apiospermum is usually sensitive to voriconazole and posaconazole. Pharmacokinetics and efficacy of nebulized voriconazole have been described in a murine model previously. We report for the first time the safe and effective use of nebulized voriconazole for the treatment of severe pulmonary infection with Scedosporium apiospermum in an adolescent with cystic fibrosis.
Copyright © 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antimycotic treatment; Cystic fibrosis; Fungal infections; Scedosporium apiospermum

Mesh:

Substances:

Year:  2013        PMID: 24263169     DOI: 10.1016/j.jcf.2013.10.014

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  9 in total

Review 1.  Fungal Pathogens in CF Airways: Leave or Treat?

Authors:  A Singh; A Ralhan; C Schwarz; D Hartl; A Hector
Journal:  Mycopathologia       Date:  2017-08-02       Impact factor: 2.574

2.  Inhaled antibiotic use is associated with Scedosporium/Lomentospora species isolation in cystic fibrosis.

Authors:  Gina Hong; Noah Lechtzin; Denis Hadjiliadis; Steven M Kawut
Journal:  Pediatr Pulmonol       Date:  2018-12-14

Review 3.  Fungus-Specific CD4 T Cells as Specific Sensors for Identification of Pulmonary Fungal Infections.

Authors:  Alexander Scheffold; Carsten Schwarz; Petra Bacher
Journal:  Mycopathologia       Date:  2017-11-22       Impact factor: 2.574

Review 4.  Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis.

Authors:  Carsten Schwarz; Dominik Hartl; Olaf Eickmeier; Andreas Hector; Christian Benden; Isabelle Durieu; Amparo Sole; Silvia Gartner; Carlos E Milla; Peter James Barry
Journal:  Mycopathologia       Date:  2017-07-31       Impact factor: 2.574

5.  Susceptibility and diversity in the therapy-refractory genus scedosporium.

Authors:  M Lackner; F Hagen; J F Meis; A H G Gerrits van den Ende; D Vu; V Robert; J Fritz; T A A Moussa; G S de Hoog
Journal:  Antimicrob Agents Chemother       Date:  2014-07-28       Impact factor: 5.191

6.  In Vivo Biomarker Analysis of the Effects of Intranasally Dosed PC945, a Novel Antifungal Triazole, on Aspergillus fumigatus Infection in Immunocompromised Mice.

Authors:  Genki Kimura; Takahiro Nakaoki; Thomas Colley; Garth Rapeport; Pete Strong; Kazuhiro Ito; Yasuo Kizawa
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 7.  Conventional Antifungals for Invasive Infections Delivered by Unconventional Methods; Aerosols, Irrigants, Directed Injections and Impregnated Cement.

Authors:  Richard H Drew; John R Perfect
Journal:  J Fungi (Basel)       Date:  2022-02-21

8.  Scedosporium apiospermum and S. prolificans mixed disseminated infection in a lung transplant recipient: An unusual case of long-term survival with combined systemic and local antifungal therapy in intensive care unit.

Authors:  Bárbara Balandin; Miriam Aguilar; Isabel Sánchez; Araceli Monzón; Isabel Rivera; Clara Salas; Miguel Valdivia; Sara Alcántara; Aris Pérez; Piedad Ussetti
Journal:  Med Mycol Case Rep       Date:  2016-04-30

Review 9.  Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections.

Authors:  Kévin Brunet; Jean-Philippe Martellosio; Frédéric Tewes; Sandrine Marchand; Blandine Rammaert
Journal:  Pharmaceutics       Date:  2022-03-14       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.